RUICONG GUAN1,3,#, KUAN ZENG1,#, MINNAN GAO1, JIANFEN LI1, HUIQI JIANG1, LU ZHANG1, JINGWEN LI1, BIN ZHANG1, YUQIANG LIU1, ZHUXUAN LIU1, DIAN WANG1, YANQI YANG1,2,*
BIOCELL, Vol.46, No.11, pp. 2455-2463, 2022, DOI:10.32604/biocell.2022.021661
Abstract Bone marrow mesenchymal stem cell (MSC)-based therapy is a novel candidate for heart repair. But ischemia-reperfusion injury leads to low viability of MSC. Dexmedetomidine (Dex) has been found to protect neurons against ischemia-reperfusion injury. It remains unknown if Dex could increase the viability of MSCs under ischemia. The present study is to observe the potential protective effect of Dex on MSCs under ischemia and its underlying mechanisms. Specific mRNAs related to myocardial ischemia in the GEO database were selected from the mRNA profiles assessed in a previous study using microarray. The most dysregulated mRNAs of the specific ones from the… More >
Login
Register
